Visceral fat and bevacizumab in metastatic colorectal cancer Response

被引：0
|
作者：
Bonnetain, F. [2 ,3 ]
Guiu, B. [4 ,5 ]
Ghiringhelli, F. [1 ,5 ]
机构：
[1] Georges Francois Leclerc Canc Ctr, Dept Oncol, Dijon, France
[2] Georges Francois Leclerc Canc Ctr, Biostat & Epidemiol Unit, Dijon, France
[3] Sch Med, Dijon, France
[4] CHU Univ Hosp, Dept Radiol, Dijon, France
[5] Univ Burgundy, INSERM, Dijon, France
来源：
GUT | 2010年 / 59卷 / 10期
关键词：
PROGRESSION-FREE SURVIVAL;
D O I：
10.1136/gut.2010.220434
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1450 / 1450
页数：1
相关论文
共 50 条
  • [1] Visceral fat and bevacizumab in metastatic colorectal cancer
    Jubb, A. M.
    GUT, 2010, 59 (10) : 1449 - 1450
  • [2] Visceral fat as a predictive marker of response to bevacizumab -based treatment in metastatic colorectal cancer.
    Miyamoto, Yuji
    Sakamoto, Yasuo
    Watanabe, Masayuki
    Baba, Hideo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab in Metastatic Colorectal Cancer
    Miyamoto, Yuji
    Oki, Eiji
    Emi, Yasunori
    Tokunaga, Shoji
    Shimokawa, Mototsugu
    Ogata, Yutaka
    Akagi, Yoshito
    Sakamoto, Yasuo
    Tanaka, Takaho
    Saeki, Hiroshi
    Maehara, Yoshihiko
    Baba, Hideo
    ANTICANCER RESEARCH, 2018, 38 (01) : 491 - 499
  • [4] Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer
    Cazeneuve, Nicolas
    Bouche, Olivier
    Leger, Julie
    Borg, Christophe
    Labbe-Devilliers, Catherine
    Lucidarme, Olivier
    Tasu, Jean-Pierre
    Manfredi, Sylvain
    Aube, Christophe
    Trillaud, Herve
    Manzoni, Philippe
    Marcus, Claude
    Terrebonne, Eric
    Douillard, Jean -Yves
    Chautard, Romain
    Lobet, Sarah
    Bleuzen, Aurore
    Lecomte, Thierry
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [5] The SLICE study: The prognostic role of visceral fat in metastatic colorectal cancer
    Basile, D.
    Lisanti, C.
    Borghi, M.
    Bartoletti, M.
    Gerratana, L.
    Bortot, L.
    Pelizzari, G.
    Corvaja, C.
    Ongaro, E.
    Garattini, S. K.
    Fanotto, V.
    Parnofiello, A.
    Cortiula, F.
    Cattaneo, M.
    Andreotti, V. J.
    Bertoli, E.
    Guardascione, M.
    Miolo, G.
    Puglisi, F.
    Buonadonna, A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [6] THE CEA BIOCHEMICAL RESPONSE OF METASTATIC COLORECTAL CANCER TREATED WITH BEVACIZUMAB
    Gonzalez-Astorga, Beatriz
    Gonzalez-Flores, Encarnacion
    Garcia Garcia, Javier
    Gonzalez-Vicente, Aranzazu
    Soberino, Jesus
    Gonzalez, Cynthia
    Ruiz, Julia
    Conde, Veronica
    Ramon Delgado, Juan
    ANNALS OF ONCOLOGY, 2012, 23 : 95 - 95
  • [7] FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
    Matsuoka, Ayumu
    Maeda, Osamu
    Ando, Yuichi
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (03): : 291 - 291
  • [8] Cetuximab or bevacizumab in metastatic colorectal cancer?
    Sclafani, Francesco
    Cunningham, David
    LANCET ONCOLOGY, 2014, 15 (10): : 1040 - 1041
  • [9] Spotlight on bevacizumab in metastatic colorectal cancer
    Susan, Paul L. McCormack
    Keam, Susan J.
    BIODRUGS, 2008, 22 (05) : 339 - 341
  • [10] FOLFOXIRI and bevacizumab in metastatic colorectal cancer
    Rahman, Ahmadur
    LANCET ONCOLOGY, 2014, 15 (13): : E590 - E590
12345